- References (2)
- Inventor Info
|Applications||FACS IF IP Fn|
|Antigen/Gene or Protein Targets||C-type lectin-like receptor 2, CLEC1b|
|Relevance||Patients with rheumatoid arthritis, an inflammatory disease associated with increased microparticle production, have raised plasma levels of microparticles that expressed CLEC-2 but not GPVI. CLEC-2 can be used to monitor platelet-derived microparticles. The observation that microparticles derived from activated platelets retain CLEC-2 but lose GPVI highlights the potential use of measurement of surface expression of platelet receptors to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases.|
|Immunogen||A recombinant extracellular fragment of human CLEC-2 (aa 68-229), which is the extracellular domain of the protein|
|Molecular Weight (kDa)||26|
|Recommended Growing Conditions||Hybridomas were cultured at 37º C and 96% relative humidity in air containing 6% CO2. Cells were grown in complete DMEM + Pen/strep + FCS was used at 10%. Cell density: Cells should be kept between 1-2x105 cells/ml and 5x105 cells/ml.|
AYP1 can block the interaction of human CLEC-2 with its endogenous ligand Podoplanin.
AYP1 does not cross react with mouse CLEC-2 when tested via FACS.
AYP1 does not detect CLEC-2 by western blot. For WB we recommend clone AYP2.
|Research Area||Cardiovascular, Immunology|
There are 2 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor